Agilent Technologies, Inc. (A) Sparks Confidence With Latest Approvals

Agilent Technologies, Inc. (NYSE:A) is one of the 10 best life sciences stocks to buy according to hedge funds.

On February 12, Agilent Technologies, Inc. (NYSE:A) announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, had been approved by the U.S. FDA. This makes it the only authorized companion diagnostic to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may qualify for treatment with KEYTRUDA (R).

Agilent Technologies, Inc. (A) Sparks Confidence With Latest Approvals

The company highlighted that the test allows pathologists to evaluate PD-L1 expression at diagnosis, supporting more informed therapy decisions in cancers where treatment options remain limited. This marks the seventh FDA-approved indication for the diagnostic in connection with KEYTRUDA.

On January 20, HSBC analyst Sidharth Sahoo initiated coverage of Agilent Technologies, Inc. (NYSE:A) with a Buy rating. He estimated a price target of $180 for the stock, yielding almost 47% upside potential. The analyst acknowledged the company as a global leader in life sciences and diagnostics. Sahoo views the company to be well-positioned for sustained bottom-line growth.

Agilent Technologies, Inc. (NYSE:A) delivers application-focused solutions, analytical instruments, and software to life sciences, diagnostics, and applied chemical markets. Its offerings include liquid chromatography systems, genomics, contract development, pathology, and biomolecular analysis. The company also offers part repair & maintenance, installations, and compliance support.

While we acknowledge the risk and potential of A as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than A and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. Follow Insider Monkey on Google News.